Navigation Links
Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
Date:11/23/2012

CHICAGO, Nov. 23, 2012 /PRNewswire/ -- Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): J.C. Penney Company, Inc. (NYSE: JCP) and Spirit AeroSystems Holdings, Inc. (NYSE: SPR). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: The New York Times Company (NYSE: NYT) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO )

To see the full Zacks #5 Rank List - Stocks to Sell Now visit: http://at.zacks.com/?id=92

Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List of Stocks to Sell Now by 80% annually (+2% vs. +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.   

Here is a synopsis of why JCP and SPR have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

J.C. Penney Company, Inc. (NYSE: JCP) announced third -quarter loss of 93 cents per share on November 12 which came behind the Zacks Consensus Estimate by 85 cents. The diluted earnings per share also fell by 1062.50% on a year-over-year basis. The Zacks Consensus Estimate for the current year slipped $1.40 per share to a loss of 97 cents in the last 30 days. Next year's estimate also dipped $1.0 per share to 65 cents per share in that time span.

Spirit AeroSystems Holdings, Inc. (NYSE: SPR) posted a third -quarter loss of $1.51 per share on November 08, which came in 84 cents wider than the average forecast. The Zacks Consensus Estimate for 2012 fell to a profit of 22 cents per share from $1.89 over the past month with 12 out of 13 covering analysts slashed forecasts. Next year's forecasts slipped 50 cents to $2.11 per share in the same time span.

Here is a synopsis of why NYT and JAZZ have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks;

The New York Times Company (NYSE: NYT) third -quarter loss of 1 cent per share, posted on October 25, lagged analysts projections by nearly 112.50%. For 2012, the Zacks Consensus Estimate moved down 12 cent in the last 30 days as 2 out of the 4 covering analysts cut back on forecasts. The forecast for next year slid 12 cents to 54 cents per share in the same time span.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported a third-quarter profit of $1.19 per share on November 8, that fell 0.83% short of the Zacks Consensus Estimate. The full-year average forecast is currently pegged at $4.38 per share, compared with the last 30 days projection of $4.45. Next year's forecast dropped 21 cents per share in the same period.

Truly taking advantage of the Zacks Rank requires the understanding of how it works.  The free special report; "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions" is available to provide this insightful background. Download a free copy now to prosper in the years to come at http://at.zacks.com/?id=93

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988, #1 Rank Stocks have generated an average annual return of +28%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained +43.8%, while the S&P 500 tumbled -37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have significantly underperformed the S&P 500 (2.8% versus +9.7%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of Zacks Rank Buy stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=94

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=95

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer:  Past performance does not guarantee future results.  Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research 
800-767-3771 ext. 9339  
support@zacks.com  
http://www.zacks.com  

 


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
3. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
4. InfuSystem Holdings, Inc. To Announce First Quarter 2012 Financial Results On May 21, 2012
5. InfuSystem Holdings, Inc. Receives Letter From NYSE MKT Regarding Timely Notice Of Record Date For 2012 Annual Meeting Of Stockholders
6. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
7. InfuSystem Holdings, Inc. Terminates "Poison Pill" Plan
8. Hill-Rom Holdings, Inc. Hosts Fiscal 2012 Third Quarter Earnings Conference Call and Webcast
9. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
10. Ultra Clean Holdings, Inc. Completes Strategic Merger with Advanced Integration Technologies
11. RoundTable Healthcare Partners Announces Sale of Aspen Surgical Products Holding, Inc. to Hill-Rom Holdings, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... According to the ... now claim the lives of 62 Americans each day.(1) Yet since 2011, the ... distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox Center ...
(Date:4/24/2017)... ANGELES, CA (PRWEB) , ... April 24, 2017 , ... ... picture is worth a thousand words. The good news for single women is that ... for Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “Reflections of God’s ... God. “Reflections of God’s Work” is the creation of published author, Jerri Broglin, a ... comfort. , “I believe this a great eye-opener for those searching for answers, ...
(Date:4/24/2017)... WA (PRWEB) , ... April 24, 2017 , ... ... leading lifestyle brands, work wear distributors and International relief organizations across the globe ... The company also offers lifestyle and work wear collections via insectshield.com . ...
(Date:4/22/2017)... , ... April 22, 2017 , ... Ecommerce sales have ... States estimated to be $394.9 billion. The consequences of rapid innovation and growth ... the limits of technology, it is every business and individual’s job to give something ...
Breaking Medicine News(10 mins):